Services
Biologic Therapeutics Development
Antibody & Protein Discovery
Target Discovery & Validation
Antibody Discovery
Antibody & Protein Production
Preclinical Testing
Structure & Biochemical Characterization
Preclinical Testing Bioassays & Immunoassays
Efficacy Models
Antibody & Protein Pharmacology
Antibody & Protein Toxicology
In Vitro
ADME
CDMO
Cell Line Development
Cell Banking
Analytical & Bioassay Quality Control
Pharmaceutical Stability Analysis
Lot Release Testing
cGMP Manufacturing
IND Regulatory
Co-Development Program by Targets
Next-IO™ T Cell related Therapeutics
Next-IO™ Anti-FGL1 Monoclonal Antibody Program
Next-IO™ Anti-FGL2 Monoclonal Antibody Program
Next-IO™ Anti-Siglec-15 Monoclonal Antibody Program
Next-IO™ Anti-TIM3 Monoclonal Antibody Program
Next-IO™ Anti-4-1BB Monoclonal Antibody Program
Next-IO™ Anti-CD19 × CD28 Bispecific Antibody Program
Next-IO™ Anti-CD27 Monoclonal Antibody Program
Next-IO™ Anti-CD40L Monoclonal Antibody Program
Next-IO™ Anti-GITR Monoclonal Antibody Program
Next-IO™ Anti-ICOS Monoclonal Antibody Program
Next-IO™ Anti-TMIGD2 Monoclonal Antibody Program
Next-IO™ Anti-HVEM/TNFRSF14 Monoclonal Antibody Program
Next-IO™ Anti-VISTA Monoclonal Antibody Program
Next-IO™ Anti-PD1 × TIM3 Bispecific Antibody Program
Next-IO™ Anti-TIGIT Monoclonal Antibody Program
Next-IO™ Anti-BTLA Monoclonal Antibody Program
Next-IO™ Anti-CD160 Monoclonal Antibody Program
Next-IO™ Anti-CTLA-4 × CD40 Combination Antibody Program
Next-IO™ Anti-PD-L1 × CD28 Bispecific Antibody Program
Next-IO™ Anti-ROR1 × CD28 Bispecific Antibody Program
Next-IO™ Anti-CD20 × CD28 Bispecific Antibody Program
Next-IO™ Anti-CD226 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-CD96 Therapeutic Monoclonal Antibody Program
Next-IO™ ICOS × PD-1 Therapeutic Bispecific Antibody Program
Next-IO™ APC related Therapeutics
Next-IO™ Anti-B7-H4 × CD3 Bispecific Antibody Program
Next-IO™ Anti-B7-H3 × CD3 Bispecific Antibody Program
Next-IO™ Anti-4-1BBL Therapeutic Fusion Protein Program
Next-IO™ Anti-CD40 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-CD70 Therapeutic Fusion Protein Program
Next-IO™ Anti-CD70 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-ICOSL Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-HHLA2 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-Galectin-9 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-CD112 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-CD155 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-OX40L Therapeutic Fusion Protein Program
Next-IO™ Anti-GITRL Therapeutic Fusion Protein Program
Next-IO™ NK Cell related Therapeutics
Next-IO™ Fusion Proteins of NKG2D Program
Next-IO™ Anti-sMIC Monoclonal Antibody Program
Next-IO™ Anti-CD48 Monoclonal Antibody Program
Next-IO™ Anti-2B4 Monoclonal Antibody Program
Next-IO™ Anti-HLA-G Monoclonal Antibody Program
Next-IO™ Anti-KIR2DL4 Monoclonal Antibody Program
Next-IO™ Anti-KIR2DL1-3 Monoclonal Antibody Program
Next-IO™ Anti-CD94/NKG2A Monoclonal Antibody Program
Next-IO™ Anti-PVR Monoclonal Antibody Program
Next-IO™ Anti-CD96 Monoclonal Antibody Program
Next-IO™ Anti-CD16 IgG Program
Next-IO™ Anti-LILRB1 Monoclonal Antibody Program
Next-IO™ Anti-KLRG1 Monoclonal Antibody Program
Next-IO™ Anti-Cadherin Monoclonal Antibody Program
Next-IO™ Anti-LLT1 Monoclonal Antibody Program
Next-IO™ Anti-NKRP1A Monoclonal Antibody Program
Next-IO™ Targeting Sialic Acid Program
Next-IO™ Anti-Nectin-2 Monoclonal Antibody Program
Next-IO™ Tumor Associated Antigens
Next-IO™ Anti-CD73 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-GPVI Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-Phosphatidylserine Monoclonal Antibody Program
Next-IO™ Anti-CD47 Therapeutic Monoclonal Antibody Program
Next-IO™ CD47 × PD-L1 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-Ang2 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-BCMA × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-CD123 × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ CD47 × PD-L1 Dual-Targeted Therapeutic Fusion Protein Program
Next-IO™ CD47 × CD19 Therapeutic Bispecific Antibody Program
Next-IO™ CD47 × MSLN Therapeutic Bispecific Antibody Program
Next-IO™ CD47 × EGFR Dual-Targeted Therapeutic Fusion Protein Program
Next-IO™ TGF-β × PD-L1 Bi-Functional Therapeutic Fusion Protein Program
Next-IO™ Anti-GPC3 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-GPC3 × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-GPA33 × CD3 Bispecific DART Protein Program
Next-IO™ Anti-GPRC5D × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-GPC3 Therapeutic CAR-T Cell Program
Next-IO™ Anti-GPC3 Therapeutic CAR-NK Cell Program
Next-IO™ Anti-MUC16 × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-CDH3 × CD3 Bispecific DART Protein Program
Next-IO™ Anti-PSMA × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-SSTR2 × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-MSLN Therapeutic Fusion Protein Program
Next-IO™ Anti-MSLN × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-CD47 × PD-L1 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-CD47 × CD20 Therapeutic Bispecific Antibody Program
Next-IO™ Anti-PD-L1 × 4-1BB Therapeutic Bispecific Antibody Program
Next-IO™ Anti-PD-L1 × 4-1BB Therapeutic Bispecific DART Program
Next-IO™ Anti-CD24 Monoclonal Antibody Program
Next-IO™ PD-L1 × TIM-3 Therapeutic Bispecific Antibody Program
Next-IO™ PD-1 × CTLA-4 Therapeutic Bispecific Antibody Program
Next-IO™ PSCA × CD3 Therapeutic Bispecific Antibody Program
Next-IO™ 4-1BB × PD-L1 Therapeutic Bispecific Antibody Program
Next-IO™ A2AR Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-Galectin-3 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-GPC3 Therapeutic Vaccine Program
Next-IO™ Anti-LAG-3 Therapeutic Monoclonal Antibody Program
Next-IO™ Anti-YTHDF1 Therapeutic Monoclonal Antibody Program
Next-IO™ c-MET × CTLA-4 Therapeutic Bispecific Antibody Program
Next-IO™ CD22 × CD19 Therapeutic CAR-T Program
Next-IO™ CD22 Therapeutic CAR-T Program
Next-IO™ CTLA-4 × OX40 Therapeutic Bispecific Antibody Program
Next-IO™ GITR × CTLA-4 Therapeutic Bispecific Antibody Program
Next-IO™ HER2 × HER3 Therapeutic Bispecific Antibody Program
Next-IO™ HER3 Therapeutic Monoclonal Antibody Program
Next-IO™ LAG-3 × PD-L1 Therapeutic Bispecific Antibody Program
Next-IO™ LAG-3 × CTLA-4 Therapeutic Bispecific Antibody Program
Next-IO™ LGR5 Therapeutic Monoclonal Antibody Program
Next-IO™ MHC I:LILRB2 Axis Therapeutic Monoclonal Antibody Program
Next-IO™ PAUF Therapeutic Monoclonal Antibody Program
Next-IO™ Chemokines & Chemokine Receptors-Related Therapeutics
Next-IO™ Anti-CCL2/CCR2 Axis Targeted Therapeutic Antibody Program
COVID-19 Recovered Patient-Derived Anti-SARS-CoV-2 Therapeutic Antibody Development
Next-IO™ Alzheimer's Disease Therapeutics
Next-IO™ Macrophages-related Therapeutics
Products
Oncology Cell Lines
Cancer Cell Lines
Reporter Cell Lines
Luciferase Cell Lines
EGFP Cell Lines
Dual Labeled Cell Lines
Gene Editing Cell Lines
KO Cell Lines
Knockin Cell Lines
Knockdown Cell Lines
Primary Cells
Stem Cells
Drug Resistant Cells
OncoImmune Cells
Oncology Kits
Consumables
Tumor Marker Kits
Oncology Assay Tools
Metabolomics Analysis Tools
Animal Models
Synthetic Gene Circuit Cells
Cell Transport Capsule Kits
ADME
Absorption
Distribution
Metabolism
Excretion
Collaborations
Company
About Us
Contact Us
Careers
Online Inquiry
Webinars
Events
Service
Product
Search
Home
Products
Oncology Kits
Human CD27 ELISA Kit, Lot 21AO-600 [Cancer Immune Checkpoint Assay Kit]
Inquiry
Datasheet
CAT#:
IOK-05-P511
Product Type:
ELISA Kit
Target:
CD27
Overview
Short Description
The kit is designed for
in vitro
quantitative measurement of Human CD27 in Plasma, Tissue Samples.
Description
Quantitative measurement of CD27 in serum, plasma, tissue homogenates and other biological fluids.
Applications
ELISA
Application Notes
Quantitative measurement of CD27 in human serum, plasma, tissue homogenates and other biological fluids.
Comment
Further details regarding sample type: Serum, plasma, tissue homogenates and other biological fluids.Absorbance (450 nm)
Target
CD27
Reactivity
Human
Detection Method
Colorimetric
Method Type
Sandwich ELISA
Analytical Method
Quantitative
Sample Type
Plasma, Tissue Samples
Specification
Components
Microplate: 96 wells
Lyophilized Standard
Sample / Standard dilution buffer
Biotin- detection antibody (Concentrated)
Antibody dilution buffer
HRP-Streptavidin Conjugate (SABC)
SABC dilution buffer
TMB substrate
Stop Solution
Wash buffer (25X)
Plate sealers
Sensitivity
< 0.094 ng/mL
Plate
Pre-coated
Assay Precision
Intra-Assay: CV < 8%, Inter-Assay: CV < 10%
Storage
4 °C
Expiry Date
6 months
Restrictions
For Research Use only
Target Details
Alternative Name
Tumor Necrosis Factor Receptor Superfamily, Member 7 (TNFRSF7)
Synonyms
TNFRSF7; S152; Tnfrsf7; Tp55; S152. LPFS2; T14; CD27 molecule; CD27 antigen; CD27; Cd27
Background
CD27 is the receptor for CD70/CD27L. It plays a role in survival of activated T-cells and in apoptosis through association with SIVA1.
Gene ID
939
UniProt
P26842
Pathways
Production of Molecular Mediator of Immune Response, Cancer Immune Checkpoints
Related Products
UCP2 Histology Assay Kit
(CAT#: ITS-1122-ZP4160)
CD81 Histology Assay Kit
(CAT#: ITS-1122-ZP686)
NOS1AP / CAPON Histology Assay Kit
(CAT#: ITS-1122-ZP2663)
PharmaOnco™ NF Cell Proliferation Assay
(CAT#: ITS-0722-HMM11)
NR1D1 Histology Assay Kit
(CAT#: ITS-1122-ZP2697)
Rhesus Monkey IL1RN ELISA Kit, Lot 21AO-1289 [Cancer Immune Checkpoint Assay Kit]
(CAT#: IOK-05-P1200)
RDC Fast decalcifying solution
(CAT#: ITS-1022-ZP103)
Feline IL-6 ELISpot Development Module, 5 Plate
(CAT#: ITS-0322-P149)
For Research Use Only | Not For Clinical Use
Online Inquiry
Send